As part of our project with Unilever, Andy McLauchlin is joining the group as a PDRA working on investigating the properties of post consumer resin.
Our long standing collaboration with the Nanomedicine Team at Liverpool has resulted in an article recently published in Nature Communications. In this paper, we highly an acceleration approach to the discover of HIV nanomedicines. We used a rapid small-scale screening method to produce large libraries of solid drug nanoparticles targeting oral dose. Through a close integration with pharmacology, we carried out iterative pharmacological and chemical evaluation to establish potential candidates for progression through to clinical manufacture. The wide applicability of our strategy has implications for multiple therapy development programmes.
See here for the full article.